Artivion, Inc. (NYSE:AORT) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in shares of Artivion, Inc. (NYSE:AORT) by 0.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,804,884 shares of the company’s stock after purchasing an additional 1,771 shares during the period. Vanguard Group Inc. owned approximately 0.07% of Artivion worth $80,192,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Quarry LP increased its stake in Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after acquiring an additional 820 shares during the last quarter. Smartleaf Asset Management LLC increased its position in Artivion by 236.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after purchasing an additional 786 shares in the last quarter. R Squared Ltd purchased a new position in Artivion in the fourth quarter valued at approximately $39,000. Arcadia Investment Management Corp MI acquired a new position in Artivion during the fourth quarter valued at approximately $43,000. Finally, Venturi Wealth Management LLC acquired a new position in Artivion during the fourth quarter valued at approximately $78,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Trading Down 1.8 %

AORT opened at $23.53 on Friday. The firm has a market capitalization of $989.35 million, a P/E ratio of -1,176.45 and a beta of 1.65. The firm’s 50 day moving average is $25.98 and its 200-day moving average is $27.50. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 52-week low of $19.36 and a 52-week high of $32.33.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). The firm had revenue of $97.31 million during the quarter, compared to analyst estimates of $100.82 million. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. Analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO James P. Mackin sold 42,156 shares of Artivion stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the completion of the sale, the chief executive officer now owns 663,882 shares in the company, valued at approximately $18,130,617.42. The trade was a 5.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jean F. Holloway sold 18,020 shares of the business’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total value of $425,452.20. Following the completion of the sale, the senior vice president now directly owns 197,184 shares of the company’s stock, valued at approximately $4,655,514.24. This represents a 8.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 90,799 shares of company stock worth $2,356,223. 8.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

AORT has been the topic of a number of research reports. Needham & Company LLC cut their target price on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Stifel Nicolaus lowered their price target on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.